Drug recall · September 14, 2016
Selegiline HCL Tablets USP 5mg recall
Why: Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, Inc. Irvine, CA 92618 Distributed by: Libertas Pharma, Inc. Montgomery, AL 36117. NDC 51862-146-06
- Lots / codes
Lot #: 14F030, 14F031, 14F032, Exp. June 2017; 15G022, Exp. July 2018
- Quantity
- 17,013 units
- Company
- Stason Pharmaceuticals, Inc., Irvine, CA
- Distribution
- North Carolina
- Initiated
- August 23, 2016 · Voluntary: Firm initiated
- Classified
- September 2, 2016
- Reported
- September 14, 2016
- Ended
- October 23, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Selegiline
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.